Probiotic supplements could ease disability, lessen depression, and improve overall health in people with relapsing-remitting multiple sclerosis (MS), according…
Articles by Marisa Wexler, MS
Lemtrada (alemtuzumab) does not have a substantial effect on blood pressure or platelet counts, and does not lead to…
Visits to the hospital related to multiple sclerosis (MS) are more common when it’s hot or when temperatures are…
More than half of people with multiple sclerosis (MS) who require an informal caregiver have experienced abuse or mistreatment…
More than one-third of people with multiple sclerosis (MS) who responded to an online U.S.-based survey are dissatisfied with…
Treatment with the diabetes medication metformin was seen to lessen cognitive impairment, improve coordination, and normalize neuronal activity in a…
A signaling protein called fractalkine helps to regulate the development of oligodendrocytes, cells of the nervous system responsible for making…
Subtle changes in structure in the hippocampus — a region of the brain involved in processing memories — can differentiate…
People with relapsing-remitting multiple sclerosis (RRMS) have switched to treatment with Gilenya (fingolimod) at an earlier stage in…
NervGen Pharma announced the formation of its multiple sclerosis (MS) clinical advisory board, a group of experts who…
Treatment with anti-CD20 antibodies reduced the loss of myelin and improved the survival of neurons in a rat model of…
The U.S. Food and Drug Administration has cleared Immunic Therapeutics to initiate two clinical trials of its investigational medication IMU-838…
In clinical trials, the investigational anti-CD20 therapy ublituximab was the first to push the annualized relapse rate (ARR) below…
Long-term disability outcomes tend to be better in people with relapsing-remitting multiple sclerosis (RRMS) who are treated early on…
Many people with multiple sclerosis (MS) start experiencing symptoms of the disease several years before being diagnosed, a new study…
Long-term use of Kesimpta (ofatumumab) among people with multiple sclerosis (MS) did not substantially lower their antibody levels, allowing…
The European Commission (EC) has approved Aubagio (teriflunomide) for the treatment of children and adolescents, ages 10 to 17,…
In the OPTIMUM clinical trial, Ponvory (ponesimod) significantly outperformed Aubagio (teriflunomide) in reducing relapse rates, fatigue, and evidence of…
T-cells in the fluid around the brain share a large percentage of receptors among different multiple sclerosis (MS) patients,…
The U.S. Food and Drug Administration (FDA) has rejected an application requesting the expansion of Aubagio (teriflunomide) for the…
A computer-based training program that exercises distinct components of attention and working memory can improve cognition in young people with…
Nearly a third of people with multiple sclerosis (MS) who are younger than 40 are not being treated with…
Immersive virtual reality may make treadmill exercise more engaging and effective for people with multiple sclerosis (MS) or other…
Due to differences in sex chromosomes, certain immune cells cause more severe disease in males than females, according to a…
Treatment with Mavenclad (clabridine) reduces the frequency of relapses in people with relapsing-remitting multiple sclerosis (RRMS), with benefits…
A new 3D model of the human nervous system is meant to mimic key processes in the development of the…
People with relapsing-remitting multiple sclerosis (RRMS) using approved oral disease-modifying therapies generally tolerate the treatments well, with real-world adverse event…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April…